NEW IMMUNOLOGICAL CHECKPOINTS FOR CANCER IMMUNOTHERAPY


Cite item

Full Text

Abstract

Members of B7-CD28 family ligands and receptors play the important role in the co-stimulation and inhibition of the T-cell mediated immune response. Blocking of the B7 family molecules inhibiting the immune response (also called immunological checkpoints), CTLA4 and PD-1 / PD-L1 promoted to important therapeutic achievements in cancer immunotherapy and improved survival of cancer patient. The recent discovery of new B7 family molecules (such as B7-H3 [CD276], B7-H4 [B7S1 / B7x / Vtcn1], B7-H5 [VISTA / PD-1H / GI24], B7-H6 and B7-H7 [HHLA2]) has expanded therapeutic possibilities for the management of cancer patients. In this article, we discuss the clinical application of known blockers of immunological checkpoints and the prospects for the use of newly discovered molecules.

About the authors

Andrei I. Chapoval

Altai State University, Russian-American Anticancer Center; Center for Innovations in Medicine, Biodesign Institute, Arizona State University

Email: andreichapoval@gmail.com
MD, PhD, Leading Researcher, Russian-American Anticancer Center, Altai State University; Barnaul, 656049, Russian Federation Barnaul, 656049, Russian Federation; 85287, Tempi, Arizona, USA

S. V Podlesnykh

Altai State University, Russian-American Anticancer Center

Barnaul, 656049, Russian Federation

E. A Kolosova

Altai State University, Russian-American Anticancer Center

Barnaul, 656049, Russian Federation

D. N Shcherbakov

Altai State University, Russian-American Anticancer Center

Barnaul, 656049, Russian Federation

References

  1. Schwartz R.H., Mueller D.L., Jenkins M.K., Quill H. T-cell clonal anergy. Cold Spring Harb. Symp. Quant Biol. 1989; 54(Pt 2): 605-10.
  2. Jenkins M.K., Chen C.A., Jung G., Mueller D.L., Schwartz R.H. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J. Immunol. 1990; 144(1): 16-22.
  3. Mahoney K.M., Rennert P.D., Freeman G.J. Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 2015; 14(8): 561-84.
  4. Lipson E.J., Drake C.G. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin. Cancer Res. 2011; 17(22): 6958-62.
  5. Galluzzi L., Kroemer G., Eggermont A. Novel immune checkpoint blocker approved for the treatment of advanced melanoma. Oncoimmunology. 2014; 3(11): e967147.
  6. Raedler L.A. Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma. Am. Health Drug Benefits. 2015; 8(Spec. Feature): 180-3.
  7. Waqar S.N., Morgensztern D. Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era? Expert Rev. Clin. Immunol. 2015; 11(8): 871-3.
  8. Alexander W. The Checkpoint Immunotherapy Revolution: What Started as a Trickle Has Become a Flood, Despite Some Daunting Adverse Effects; New Drugs, Indications, and Combinations Continue to Emerge. P T. 2016; 41(3): 185-91.
  9. Chapoval A.I., Ni J., Lau J.S., Wilcox R.A., Flies D.B., Liu D. et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat. Immunol. 2001; 2(3): 269-74.
  10. Wang J., Chong K.K., Nakamura Y., Nguyen L., Huang S.K., Kuo C. et al. B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma. J. Invest. Dermatol. 2013; 33(8): 2050-8.
  11. Zhou Z., Luther N., Ibrahim G.M., Hawkins C., Vibhakar R., Handler M.H. et al. B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. J. Neurooncol. 2013; 111(3): 257-64.
  12. Xu Y.H., Zhang G.B., Wang J.M., Hu H.C. B7-H3 and CD133 expression in non-small cell lung cancer and correlation with clinicopathologic factors and prognosis. Saudi Med. J. 2010; 31(9): 980-6.
  13. Yamato I., Sho M., Nomi T., Akahori T., Shimada K., Hotta K. et al. Clinical importance of B7-H3 expression in human pancreatic cancer. Br. J. Cancer. 2009; 101(10): 1709-16.
  14. Crispen P.L., Sheinin Y., Roth T.J., Lohse C.M., Kuntz S.M., Frigola X. et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin. Cancer Res. 2008; 14(16): 5150-7.
  15. Ingebrigtsen V.A., Boye K., Nesland J.M., Nesbakken A., Flatmark K., Fodstad Ш. B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome. BMC Cancer. 2014; 14: 602.
  16. Zang X., Sullivan P.S., Soslow R.A., Waitz R., Reuter V.E., Wilton A. et al. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol. 2010; 23(8): 1104-12.
  17. Arigami T., Narita N., Mizuno R., Nguyen L., Ye X., Chung A. et al. B7-H3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann. Surg. 2010; 252(6): 1044-51.
  18. Wu C.P., Jiang J.T., Tan M., Zhu Y.B., Ji M., Xu K.F. et al. Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J. Gastroenterol. 2006; 12(3): 457-9.
  19. Loo D., Alderson R.F., Chen F.Z., Huang L., Zhang W., Gorlatov S. et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin. Cancer Res. 2012; 18(14): 3834-45.
  20. Sica G.L., Choi I.H., Zhu G., Tamada K., Wang S.D., Tamura H. et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity. 2003; 18(6): 849-61.
  21. Prasad D.V., Richards S., Mai X.M., Dong C. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity. 2003; 18(6): 863-73.
  22. Suh W.K., Wang S., Duncan G.S., Miyazaki Y., Cates E., Walker T. et al. Generation and characterization of B7-H4/B7S1/B7x-deficient mice. Mol. Cell Biol. 2006; 26(17): 6403-11.
  23. Zhu G., Augustine M.M., Azuma T., Luo L., Yao S., Anand S. et al. B7-H4-deficient mice display augmented neutrophil-mediated innate immunity. Blood. 2009; 113(8): 1759-67.
  24. Choi I.H., Zhu G., Sica G.L., Strome S.E., Cheville J.C., Lau J.S. et al. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J. Immunol. 2003; 171(9): 4650-4.
  25. Krambeck A.E., Thompson R.H., Dong H., Lohse C.M., Park E.S., Kuntz S.M. et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc. Natl. Acad. Sci. USA. 2006; 103(27): 10391-6.
  26. Salceda S., Tang T., Kmet M., Munteanu A., Ghosh M., Macina R. et al. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp. Cell Res. 2005; 306(1): 128-41.
  27. Yao Y., Wang X., Jin K., Zhu J., Wang Y., Xiong S. et al. B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subset of brain tumor stem-like cells. J. Neurooncol. 2008; 89(2): 121-9.
  28. Zhang L., Wu H., Lu D., Li G., Sun C., Song H. et al. The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus. Oncogene. 2013; 32(46): 5347-58.
  29. Dangaj D., Scholler N. Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses. Oncoimmunology. 2013; 2(8): e25913.
  30. Wang L., Rubinstein R., Lines J.L., Wasiuk A., Ahonen C., Guo Y. et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 2011; 208(3): 577-92.
  31. Flies D.B., Wang S., Xu H., Chen L. Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J. Immunol. 2011; 187(4): 1537-41.
  32. Lines J.L., Pantazi E., Mak J., Sempere L.F., Wang L., O’Connell S. et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res. 2014; 74(7): 1924-32.
  33. Byers J.T., Paniccia A., Kaplan J., Koenig M., Kahn N., Wilson L. et al. Expression of the Novel Costimulatory Molecule B7-H5 in Pancreatic Cancer. Ann. Surg. Oncol. 2015; 22(Suppl. 3): S1574-9.
  34. Brandt C.S., Baratin M., Yi E.C., Kennedy J., Gao Z., Fox B. et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 2009; 206(7): 1495-503.
  35. Guo J.G., Guo C.C., He Z.Q., Liu Z.G., Wang Y., Mou Y.G. Clinical significance of B7-H6 protein expression in astrocytoma. Onco Targets Ther. 2016; 9: 3291-7.
  36. Flajnik M.F., Tlapakova T., Criscitiello M.F., Krylov V., Ohta Y. Evolution of the B7 family: co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7’s historical relationship with the MHC. Immunogenetics. 2012; 64(8): 571-90.
  37. Zhao R., Chinai J.M., Buhl S., Scandiuzzi L., Ray A., Jeon H. et al. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc. Natl. Acad. Sci. USA. 2013; 110(24): 9879-84.
  38. Janakiram M., Chinai J.M., Fineberg S., Fiser A., Montagna C., Medavarapu R. et al. Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein. Clin. Cancer Res. 2015; 21(10): 2359-66.

Copyright (c) 2017 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies